How 2026 Medtech Trends Are Reshaping North American Manufacturing and Trade

The medical technology industry is not only a clinical sector; it is a manufacturing, logistics, and trade sector. Devices such as imaging systems, cardiovascular catheters, orthopedic implants, surgical robots, and continuous monitoring tools cross North American borders multiple times before they reach a patient. The region’s competitiveness in medical technology therefore depends as much on trade policy and industrial strategy as on clinical breakthrough.

Clarivate’s recently released report, Medtech Trends to Watch 2026, identifies five global forces that will shape the sector: the expansion of China’s volume-based procurement, the shift to outpatient care, tariff-driven supply chain pressure, the rise of GLP-1 therapies, and the emergence of platform-based competition. For trade and manufacturing analysts, these trends have direct implications for North America’s cross-border production networks, investment decisions, and regional integration.

Executive Summary

• China’s volume-based procurement is no longer a localized pricing issue. It is changing global price expectations and forcing North American companies to reconsider portfolio strategy and market diversification.
• Payment changes that shift more procedures into ambulatory surgical centers are altering device design, inventory structures, and logistics demand.
• Tariff exposure, geopolitical risk, and material cost instability are pushing medtech companies to build more flexible manufacturing footprints across USMCA markets.
• GLP-1 therapies are beginning to reshape clinical volumes, requiring device manufacturers to rebalance capacity across therapy categories.
• Robotics, imaging, navigation, and digital workflow tools are shifting competitive advantage from individual products to integrated platforms, placing new demands on digital and data infrastructure.

Introduction

North America has one of the world’s most sophisticated medical technology markets. The United States serves as the primary R&D and commercialization center, Canada contributes advanced materials and AI-enabled diagnostics, and Mexico has become a major manufacturing and export platform for disposable and assembled devices.

The strength of this regional system is tied to commercial policy. USMCA rules of origin, regulatory cooperation, and cross-border logistics allow companies to design production networks that are more resilient than purely overseas sourcing models. The 2026 trends outlined by Clarivate, however, suggest that the system will face new stresses and opportunities in the coming years.

Main Analysis

1. China’s VBP expansion redefines global pricing and portfolio strategy

Clarivate identifies China’s latest national volume-based procurement round as one of the most consequential shifts in global medtech pricing. What began as a policy to expand patient access has become a market-structuring mechanism. The newest rules use more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers.

For U.S. and Canadian medtech multinationals, the implications are strategic, not just commercial. China has historically offered both high volumes and relatively high prices for advanced devices. As VBP compresses prices, companies are likely to separate product portfolios into global innovation platforms and lower-cost China-specific variants.

This will have consequences for manufacturing strategy in North America. The most advanced devices are increasingly likely to be developed and produced for the U.S., Canada, and other high-value markets. Trade policy, export controls, and supply chain security become more important as the industry separates politically accessible markets from innovation-driven markets.

2. Outpatient care migration changes product formats and logistics

The report notes that the 2026 CMS Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center final rule is accelerating the shift of procedures into outpatient settings. Higher-acuity procedures, including certain cardiac ablations, are becoming eligible for ambulatory surgical centers.

This trend changes the types of products hospitals and clinics purchase. ASCs have less storage space than hospitals, require efficient case setup, and favor devices that are smaller, easier to use, and often single-use. The shift will affect distribution strategies, packaging design, and inventory management.

From a trade perspective, the migration to outpatient care strengthens the role of third-party logistics providers and cross-border distribution in both the United States and Mexico. Just-in-time replenishment across the USMCA region requires better visibility and stronger coordination between manufacturers, customs brokers, and freight forwarders.

3. Tariff exposure is reshaping manufacturing geography

Clarivate’s supply chain analysis points to tariffs, geopolitical factors, and fluctuating material costs as forces that are undermining long-standing assumptions about production location. Medical device companies have traditionally concentrated manufacturing to obtain scale and regulatory efficiency. That approach is being replaced by multi-region manufacturing networks designed to reduce single-country risk.

The shift is a critical opportunity for North America. Companies seeking to move production out of Asia will look first to Mexico, which has an established medical device manufacturing base and trade preferences into the U.S. market. Experience in precision assembly, regulatory compliance, and cross-border production makes Mexico an attractive nearshoring option.

The United States remains central to advanced manufacturing, including components requiring high automation, sterile processing, and sophisticated quality systems. Canada is smaller in volume but plays an important role in specialized device design and data-enabled product platforms.

To qualify for USMCA preferences, products must meet originating status and regional value content requirements. That creates an incentive for manufacturers to deepen North American content in everything from stainless steel components to electronic boards and sterile packaging.

4. GLP-1 therapies create uneven demand shifts across medtech

The fast adoption of GLP-1 receptor agonists has become a major force in health economics. Clarivate’s report observes that while bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1 therapies are changing referral patterns. Some bariatric procedure volumes are under sharper pressure than others, and downstream effects are emerging in diabetes, sleep apnea, and cardiovascular monitoring.

The trade and manufacturing significance lies in portfolio rebalancing. Device manufacturers that rely on high-volume bariatric surgery may need to shift plant capacity and supply chain investment toward products associated with chronic disease management. Sensors, implantable monitors, diagnostic devices, and digital care tools all have different material and component profiles than traditional surgical instruments.

Flexibility in North American manufacturing will become a key competitive advantage. Mexico’s electronics and assembly capabilities, Canada’s software and AI ecosystem, and the U.S. regulatory market together allow companies to move more quickly when clinical demand patterns shift.

5. Platform-based competition depends on data, software, and digital trade

Clarivate also highlights the increasing role of enabling technologies such as robotics, imaging, navigation, and digital workflow software. These are no longer simply adjacent to medical procedures. They are becoming the architecture through which manufacturers compete.

Platform-based competition changes the boundaries of medical device manufacturing. A surgical robot is part hardware, part software, part data platform, and part service ecosystem. Imaging and navigation tools generate large datasets used for AI training and real-time decision support.

This creates a new trade policy dimension. Cross-border data flows are essential for software updates, remote monitoring, and AI improvement. North American policymakers will need to balance digital regulation with the need to allow medical device platforms to operate seamlessly across the United States, Canada, and Mexico.

The region has strong digital foundations. U.S. software and semiconductor leadership, Canadian AI research, and Mexican high-tech manufacturing can form a competitive North American platform. That result is not automatic; it requires deliberate investment in digital infrastructure and regulatory interoperability.

Trade Impact

The trends identified in Clarivate’s report are likely to affect the medical device trade in several measurable ways.

• USMCA preference utilization will increase. As manufacturers add North American content, more medical devices will come to depend on maintaining originating status under the trade agreement.
• Supply chain financing will grow. Multi-region production requires more working capital and places new demands on trade finance and supply chain risk management.
• Customs compliance becomes more complex. Device importers must track component origins more precisely to manage tariff risk and take full advantage of regional preferences.
• Logistics networks will reorganize around regional hubs. The shift away from single-country production will create stronger demand for cross-border trucking, near-port warehousing, and temperature-controlled distribution in the USMCA corridor.
• Smaller suppliers face higher barriers but more opportunity. Original equipment manufacturers increasingly expect contract manufacturers to demonstrate supply chain visibility and regional capacity. That raises compliance costs but also rewards suppliers that can provide integrated cross-border services.

Regional Perspective

United States

The United States remains the largest and most profitable medtech market in the world. It also has the deepest ecosystem for regulatory science, clinical research, and advanced component manufacturing. In this new environment, the U.S. is likely to keep high-value design, software integration, and complex sterile manufacturing, while working to ensure that trade policy supports rather than disrupts continental supply chains.

Canada

Canada’s medtech sector is smaller but strong in diagnostic software, AI, imaging, and connected health technologies. For Canada, the opportunity is to secure a role in North American platform ecosystems. Canadian companies should seek better integration with U.S. manufacturing networks and ensure that digital trade rules allow Canadian engineers to collaborate with U.S. and Mexican partners without additional data friction.

Mexico

Mexico is poised to be the primary manufacturing expansion node for medical devices in North America. It already has significant production of disposable devices, orthopedic products, and electronic assemblies. The next stage will involve moving into higher-complexity devices and automated manufacturing systems. Investment in workforce training, clean energy, and infrastructure will be required to sustain this shift.

USMCA

USMCA is not simply a tariff agreement. It is a framework for regional industrial strategy. Medical device manufacturers are increasingly likely to treat the three markets as a single production ecosystem. Rules of origin, regulatory cooperation, and infrastructure investment will determine whether that ecosystem is globally competitive.

The review process under USMCA will also test the agreement’s ability to respond to new challenges. As medical devices incorporate more software and connectivity, trade rules must evolve to address cybersecurity, data localization, and digital industrial standards.

Future Outlook

Over the next three to five years, North American medical device manufacturing and trade will be defined by four strategic themes.

• Resilience through redundancy. Companies will build smaller, more diversified production footprints across multiple states and provinces rather than relying on one low-cost site.
• Portfolio stratification by market. Products will increasingly be created for separate market segments: high-value innovation for North America and Europe, price-sensitive variants for procurement-driven markets.
• Convergence with digital industry. Medtech firms will compete less as device manufacturers and more as health platforms. This will attract investment from software companies and create new alliances across the digital economy.
• Deepening nearshoring in Mexico. Mexico’s role will expand beyond assembly to include engineering design, automation, and regional logistics management, supported by investment in border infrastructure and industrial parks.

North America’s competitiveness will depend on whether its three governments can coordinate on infrastructure, technology policy, and workforce development. The private sector is already moving ahead with regional supply chain strategies. Public policy must keep pace.

Conclusion

The trends highlighted in Clarivate’s 2026 medtech report are not only medical or commercial. They are deeply connected to trade policy, manufacturing investment, and regional integration. In China, VBP is rewriting the economics of global market access. In the United States, cost pressure and site-of-care changes are shifting demand. In global supply chains, tariffs and geopolitical risk are accelerating nearshoring. In technology, platform competition is making software and data as important as sterile manufacturing.

For the North American trade region, the path forward is not to resist those pressures but to build a more integrated industrial system. USMCA, infrastructure investment, and cross-border logistics networks can turn medtech disruption into regional advantage, but only if companies and policymakers align their strategies.

The next few years will test whether the region can move beyond conversation and create durable, flexible medical device supply chains designed for a fragmented global economy. North America has the scientific, manufacturing, and policy tools to lead that transition. The choices now being made in factories, trade offices, and investment committees will determine whether it does.

Key Takeaways

• Medical device trade is becoming more regionally integrated even as global market structures fragment.
• China’s volume-based procurement continues to change the commercial calculus for U.S.-based device multinational.
• Tariffs and geopolitical volatility are accelerating manufacturing investment in U.S., Canadian, and Mexican supply chains.
• The shift to outpatient care is changing device design, packaging, and logistics requirements.
• Platform-based competition means digital trade rules and data infrastructure are as important as physical supply chain capacity.

Sources

• Clarivate. “5 medtech trends to watch in 2026.” April 28, 2026. Link